The Peptide Fad: How Convenience Stores Are Selling Unsafe Products

From Brooklyn Bodega to Lab Test

When I first heard about the viral peptides being sold in corner stores, I was intrigued by how a product once reserved for research laboratories had found its way into the hands of everyday consumers. I decided to take a closer look at this trend and visited Mr. Green, a bodega located on Bedford Avenue in Brooklyn, where the substances are available for sale.

What I discovered wasn't just shocking—it was alarming. The store offered a selection of injectable peptides—PT-141 for low libido, BPC-157 for healing, NAD+ for cellular repair, and retatrutide for weight loss—all sold at a steep price point. For $376.20, I acquired four samples that I later submitted to Finnrick Labs, an independent testing company based in Austin.

"What we offer is simply a label claim analysis. So you send us what you claim to think it is, and then we run it against a standard and verify whether or not it's the right compound," said Marco Krause, CEO of the lab that performed the tests.

The results were sobering: none of the samples contained the active ingredients listed on their labels. In fact, they had no detectable peptides at all. The vials were mislabeled or, more concerning, contained substances that had degraded beyond recognition—possibly due to improper storage or contamination during transit.

This isn't an isolated incident. Jeff Colhoun, founder of Peptide Critic, recently conducted similar testing on peptides purchased from Smoker's World, another local retailer. His lab results also showed no trace of the active ingredients. In both cases, we're left with a product that offers nothing but confusion and potential risk.

A Market in Crisis

What makes this situation even more disquieting is how widespread it has become. The global peptide market is estimated to be worth up to $3 billion, driven by the popularity of influencers like Joe Rogan and Robert F. Kennedy Jr., who have promoted these products without scientific backing.

The FDA has been increasingly involved in trying to regulate this space, especially as companies begin selling peptides through telehealth platforms such as Hims and Mochi. Yet enforcement remains patchy—especially when it comes to retail outlets that sell products labeled as 'research use only' but are marketed directly to the public.

It's not just about legality; it's about safety. As Darshan Kulkarni, a pharmaceutical regulatory compliance attorney, noted: "We have no idea what's in them. We have no idea about the safety, accuracy profile, or whether they're adulterated or misbranded." In a properly regulated industry, such issues would be rare—products are barcoded, visually inspected, and batch-tested to ensure authenticity.

But when someone purchases peptides at a convenience store, they're flying blind. There's no oversight, no verification process, and certainly no accountability from the sellers themselves.

The Human Cost

This lack of control comes with real consequences. A recent case in the Bronx highlighted the dangers: a woman died after receiving an injection from an unlicensed medical spa that contained substances not intended for human consumption.

While it's unclear if that particular incident was connected to retail peptides, it serves as a stark reminder of how quickly things can go wrong when safety isn't prioritized. Even products that appear harmless—like those sold at Mr. Green—can be mislabeled or improperly stored, leading to wasted money and potential health risks.

I reached out to Fred Mills, executive director at Americans for Safe and Effective Medicines, who confirmed my concerns: "We're legitimizing products, and we have no idea what's in them." He's seen firsthand the increasing number of individuals purchasing these substances without proper medical oversight. For a field that requires precision and accountability, the current landscape is dangerously chaotic.

Regulatory Gaps

The FDA has issued warnings to companies marketing these products, particularly those making false or misleading claims about their efficacy. However, enforcement remains inconsistent—especially when it comes to brick-and-mortar locations selling peptides labeled as non-human consumption.

This regulatory vacuum isn't new. It's rooted in the broader political shift toward deregulation under the Trump administration, which emphasized that "regulation stifles innovation" and believed patients should be able to decide what products they use. While well-intentioned, this approach has created a breeding ground for unregulated substances entering the market.

In one notable case, a man in South Bend, Indiana, was sentenced to six years in prison for illegally importing peptides from China that were adulterated with steroids. Yet despite such cases, many businesses continue to sell these products with little risk of legal consequences.

Where Do We Go From Here?

The rise of the peptide market reflects a larger cultural trend: consumers are increasingly seeking quick fixes and self-improvement through supplements and unregulated therapies. But this hunger for instant results shouldn't come at the expense of public safety.

As someone who has spent years covering the intersection of business, policy, and technology, I see a clear need for stronger regulatory frameworks that protect consumers while still allowing room for innovation. We must demand better accountability from sellers, more robust testing practices, and stricter penalties for those who exploit loopholes in the system.

The story of Mr. Green and its peptide offerings isn't just about one bodega—it's about a national conversation on how we define risk, safety, and responsibility in the marketplace. Until that conversation changes, consumers will continue to be at risk from products they can't trust.

In the meantime, if you're considering trying any of these substances, I strongly encourage consulting with a healthcare professional before proceeding—because the cost of misinformation may be far too high.